

## SuperSonic Imagine to Demonstrate Breakthrough Ultrasensitive Technology for Microvascular Imaging for the First Time at the French Radiology Congress

**Aix-en-Provence, France, October 15, 2015** - SuperSonic Imagine (Euronext: SSI, FR0010526814), a company specializing in ultrasound medical imaging equipment, announces the introduction of breakthrough ultrasensitive microvascular imaging technology at the 63<sup>rd</sup> Journées Françaises de Radiologie (JFR), which will take place in Paris Oct 16<sup>th</sup> – 19<sup>th</sup>, 2015.

Already the pioneers of ShearWave™ Elastography, SuperSonic Imagine now introduces the next wave in ultrasound innovation – AngioPLUS\* – PLanewave UltraSensitive imaging. AngioPLUS is a significant advancement in Color Doppler Imaging. Conventional Doppler is limited in its ability to show microvascular slow flow. AngioPLUS significantly improves color sensitivity and spatial resolution, resulting in the next level of microvascular imaging to visualize flows that couldn't be seen before. Soon available on Aixplorer®, this innovation will provide highly detailed real-time information to physicians, which is key in diagnosing cancerous lesions. Lesion microvascularization and vessel flow are important indicators of a potential malignancy in areas such as breast, lymph nodes, thyroid and liver. This technique is also valuable for musculoskeletal assessments to help identify low-grade tendon inflammation.

*“The AngioPLUS technology significantly improves flow sensitivity in color imaging. This innovation allows physicians to quickly and accurately address challenging clinical situations such as characterizing fortuitously discovered focal liver lesions and renal blood flow disturbance. We believe AngioPLUS can help avoid additional imaging or biopsy procedures”* commented Prof. Jean-Michel Correas, Vice Chairman of the Adult Radiology Department, Necker University Hospital, Paris.

This innovation is possible thanks to the unique UltraFast™ software platform of Aixplorer that can acquire images 200 times faster than conventional ultrasound systems. The flow of microvessels is very slow and challenging to image with conventional platforms. With its ability to help physicians see more detailed images, AngioPLUS could help minimize the use of intravenously administered contrast imaging agents currently used to improve sensitivity and resolution to image microvessels. In addition to liver and renal applications as quoted by Prof. Correas, AngioPLUS has demonstrated superb microvascular structures in the thyroid, breast, lymph nodes and in musculoskeletal applications detailing inflammation.

The UltraFast platform is the foundation of two additional breakthrough innovations which have changed the paradigm of ultrasound imaging: ShearWave Elastography and UltraFast Doppler. ShearWave Elastography is used to assess and quantify tissue stiffness, an important parameter in diagnosing potentially malignant tissue. UltraFast Doppler combines Color Flow Imaging and Pulsed Wave Doppler into one simple exam, providing physicians exam results simultaneously and helping increase patient throughput. This latest innovation, AngioPLUS, is a significant advancement to the “arsenal” of non-invasive diagnostic tools for cancer diagnosis.

*“As the pioneers of ShearWave Elastography, we are thrilled to participate in this year’s JFR meeting and introduce the next leap forward in ultrasound innovation: AngioPLUS. The combination of our ShearWave technology measuring tissue stiffness and AngioPLUS for microvascular visualization brings a suite of state of the art imaging to physicians. AngioPLUS further demonstrates our deep commitment to delivering innovative ultrasound technology to radiologists in a broad range of clinical applications such as breast, liver, thyroid and musculoskeletal exams,”* commented Jacques Souquet, SuperSonic Imagine’s Chief Innovation Officer.

AngioPLUS as well as other innovations will be demonstrated at SuperSonic Imagine’s booth at JFR (# 217).

SuperSonic Imagine’s Symposium will take place on Sunday, October 18<sup>th</sup> at 12:30 CET (Room 251). Leading physicians will discuss “The Clinical Benefits of ShearWave Elastography in Daily Practice: musculoskeletal, liver and testicular.”

*\*AngioPLUS Imaging is pending regulatory approval*

### **About SuperSonic Imagine**

Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The company designs, develops and markets a revolutionary ultrasound system, Aixplorer®, with an UltraFast™ platform that can acquire images 200 times faster than conventional ultrasound systems. Aixplorer® is the only system that can image two types of waves: ultrasound waves ensure excellent image quality and shear waves, which allow physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner. This innovation, ShearWave™ Elastography, significantly improves the detection and characterization of numerous pathologies in several applications including breast, thyroid, liver and prostate. SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer® in the main global markets. Over the past years, SuperSonic Imagine enjoyed the backing of several prestigious investors, among which Auriga Partners, Edmond de Rothschild Investment Partners, Bpifrance, Omnes Capital and NBGI.

For more information about SuperSonic Imagine, please go to [www.supersonicimagine.com](http://www.supersonicimagine.com)

#### **SuperSonic Imagine**

Marketing & Communication  
Emmanuelle Vella  
[emmanuelle.vella@supersonicimagine.com](mailto:emmanuelle.vella@supersonicimagine.com)  
+33 4 86 79 03 27

#### **NewCap**

Investor Relations - EU  
Pierre Laurent / Florent Alba  
[supersonicimagine@newcap.fr](mailto:supersonicimagine@newcap.fr)  
+33 1 44 71 98 55

#### **Blueprint Life Science Group**

Investor Relations - US  
Candice Knoll  
[cknoll@bplifescience.com](mailto:cknoll@bplifescience.com)  
+1 415 375 3340 Ext. #4

#### **ComCorp**

Media Relations  
Adelaïde Manester  
[amanester@comcorp.fr](mailto:amanester@comcorp.fr)  
+33 1 58 18 32 58

